Key Takeaways
- • He Jiankui, the Chinese scientist infamously convicted in 2020 for creating the first CRISPR-edited babies, has received a funding offer from Ryan Shea, founder and CEO of cryptocurrency firm Opus, to commercialize a new genetic engineering project targeting Alzheimer's disease prevention.
- • The June 2024 outreach represents a significant shift in He's standing within certain tech and crypto circles, despite his status as a pariah in mainstream science following his 2018 revelation of three CRISPR-edited births and subsequent 3-year prison sentence for "illegal medical practices."
- • He's proposed new venture would use CRISPR gene-editing on human embryos to reduce future Alzheimer's disease risk, positioning the technology for commercial application in the biotech space.
- • The funding offer highlights emerging tensions between cryptocurrency entrepreneurs and traditional scientific governance, with crypto-backed capital increasingly targeting controversial or marginalized biomedical researchers and ventures.
Summary
He Jiankui, the controversial Chinese scientist whose 2018 CRISPR gene-editing experiments on human embryos resulted in three births and triggered a global scientific reckoning, has attracted financial backing from the cryptocurrency sector. On June 17, 2024, Ryan Shea, founder and CEO of the cryptocurrency firm Opus, sent He an unsolicited email offering funding and operational support for a new commercial venture. The proposal centers on using CRISPR technology to edit human embryos with the stated goal of reducing future risk of Alzheimer's disease.
He's rehabilitation attempt occurs against a backdrop of significant professional disgrace. His 2018 revelation that he had secretly conducted genetic experiments resulting in the birth of CRISPR-edited children triggered international outcry over ethical violations and scientific misconduct. Chinese authorities subsequently convicted him in 2020 of "illegal medical practices," imposing a 3-year prison sentence. The episode made him a pariah among the global scientific establishment and remains a watershed moment in bioethics debates surrounding germline editing.
Shea's June communication explicitly framed He as a visionary willing to challenge scientific orthodoxy. "The world needs more brave scientists like yourself who are willing to challenge conventional wisdom and take calculated risks to help humanity cure disease," Shea wrote, directly contrasting the entrepreneur's perspective with mainstream scientific institutions' rejection of He's work. This positioning reflects a broader pattern in which cryptocurrency and fintech entrepreneurs have positioned themselves as alternative funding sources for biomedical research deemed too risky or ethically fraught for traditional venture capital or institutional support.
The funding offer underscores the intersection of cryptocurrency capital, alternative biomedicine ventures, and governance challenges in emerging biotech spaces. As traditional scientific institutions and regulatory bodies maintain skepticism toward He's work, crypto-backed capital has emerged as a potential funding pathway for previously marginalized researchers and controversial genetic engineering projects. The development raises questions about oversight, accountability, and the role of unregulated financial markets in directing biomedical innovation toward projects with significant ethical and regulatory uncertainties.
He's rehabilitation attempt occurs against a backdrop of significant professional disgrace. His 2018 revelation that he had secretly conducted genetic experiments resulting in the birth of CRISPR-edited children triggered international outcry over ethical violations and scientific misconduct. Chinese authorities subsequently convicted him in 2020 of "illegal medical practices," imposing a 3-year prison sentence. The episode made him a pariah among the global scientific establishment and remains a watershed moment in bioethics debates surrounding germline editing.
Shea's June communication explicitly framed He as a visionary willing to challenge scientific orthodoxy. "The world needs more brave scientists like yourself who are willing to challenge conventional wisdom and take calculated risks to help humanity cure disease," Shea wrote, directly contrasting the entrepreneur's perspective with mainstream scientific institutions' rejection of He's work. This positioning reflects a broader pattern in which cryptocurrency and fintech entrepreneurs have positioned themselves as alternative funding sources for biomedical research deemed too risky or ethically fraught for traditional venture capital or institutional support.
The funding offer underscores the intersection of cryptocurrency capital, alternative biomedicine ventures, and governance challenges in emerging biotech spaces. As traditional scientific institutions and regulatory bodies maintain skepticism toward He's work, crypto-backed capital has emerged as a potential funding pathway for previously marginalized researchers and controversial genetic engineering projects. The development raises questions about oversight, accountability, and the role of unregulated financial markets in directing biomedical innovation toward projects with significant ethical and regulatory uncertainties.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.